Pharming Group (PHAR) News Today → Tiny AI projects with huge promise hiding in plain sight … (From Weiss Ratings) (Ad) Free PHAR Stock Alerts $9.37 -0.26 (-2.70%) (As of 11:29 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 2:45 AM | finanznachrichten.dePharming Group N.V.: Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025May 15 at 2:45 AM | finance.yahoo.comPharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025May 14 at 2:21 PM | marketbeat.comPharming Group (NASDAQ:PHAR) Sees Strong Trading VolumePharming Group (NASDAQ:PHAR) Sees Large Volume IncreaseMay 13 at 5:11 PM | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Down to $10.00Pharming Group (NASDAQ:PHAR) Shares Gap Down to $10.00May 13 at 4:59 AM | americanbankingnews.comEquities Analysts Set Expectations for Pharming Group's FY2025 Earnings (NASDAQ:PHAR)May 12 at 9:19 AM | seekingalpha.comPharming Group N.V. 2024 Q1 - Results - Earnings Call PresentationMay 11, 2024 | americanbankingnews.comPharming Group Expected to Post Q3 2024 Earnings of $0.01 Per Share (NASDAQ:PHAR)May 10, 2024 | marketbeat.comPharming Group (NASDAQ:PHAR) to Post Q3 2024 Earnings of $0.01 Per Share, HC Wainwright ForecastsPharming Group (NASDAQ:PHAR - Free Report) - Equities researchers at HC Wainwright issued their Q3 2024 earnings per share (EPS) estimates for Pharming Group in a research report issued to clients and investors on Wednesday, May 8th. HC Wainwright analyst J. Pantginis forecasts that the company wMay 8, 2024 | finanznachrichten.dePharming Group N.V.: Pharming Group reports first quarter 2024 financial results and provides business updateMay 7, 2024 | markets.businessinsider.comWhat Wall Street expects from Pharming Group NV's earningsMay 6, 2024 | americanbankingnews.comPharming Group (PHAR) Scheduled to Post Quarterly Earnings on WednesdayMay 2, 2024 | marketbeat.comPharming Group (NASDAQ:PHAR) Sees Unusually-High Trading VolumePharming Group (NASDAQ:PHAR) Sees Large Volume IncreaseMay 1, 2024 | marketbeat.comPharming Group (PHAR) to Release Quarterly Earnings on WednesdayPharming Group (NASDAQ:PHAR) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports.April 30, 2024 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Down to $9.91Pharming Group (NASDAQ:PHAR) Shares Gap Down to $9.91April 26, 2024 | marketbeat.comPharming Group (NASDAQ:PHAR) Trading Down 8.8%Pharming Group (NASDAQ:PHAR) Shares Down 8.8%April 24, 2024 | finance.yahoo.comPharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact AwardsApril 24, 2024 | finance.yahoo.comPharming Group to report first quarter 2024 financial results on May 8April 19, 2024 | finanznachrichten.dePharming Group N.V.: Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025April 18, 2024 | finanznachrichten.dePharming Group N.V.: Pharming Group announces the placement of €100 million convertible bonds due 2029April 18, 2024 | finance.yahoo.comPharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025April 15, 2024 | marketbeat.comPharming Group (NASDAQ:PHAR) Stock Price Down 6.8%Pharming Group (NASDAQ:PHAR) Shares Down 6.8%April 9, 2024 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Down 5% Pharming Group (NASDAQ:PHAR) Trading Down 5%April 8, 2024 | finance.yahoo.comPharming announces completion of enrollment in pediatric clinical trial of leniolisibApril 4, 2024 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Down to $10.96Pharming Group (NASDAQ:PHAR) Shares Gap Down to $10.96April 4, 2024 | finance.yahoo.comPharming Group announces the filing of its 2023 Annual Report and Form 20-FMarch 19, 2024 | marketbeat.comPharming Group (NASDAQ:PHAR) Stock Price Down 5%Pharming Group (NASDAQ:PHAR) Stock Price Down 5%March 18, 2024 | marketbeat.comPharming Group (NASDAQ:PHAR) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $37.00 target price on shares of Pharming Group in a research note on Thursday.March 18, 2024 | msn.comUber to pay $178 million in Australia taxi class action settlementMarch 15, 2024 | msn.comPharming reports Q4 resultsMarch 14, 2024 | seekingalpha.comPharming Group N.V. 2023 Q4 - Results - Earnings Call PresentationMarch 13, 2024 | marketbeat.comPharming Group (NASDAQ:PHAR) Stock Price Down 6.5%Pharming Group (NASDAQ:PHAR) Trading Down 6.5%March 12, 2024 | marketbeat.comPharming Group (NASDAQ:PHAR) Short Interest Up 900.0% in FebruaryPharming Group (NASDAQ:PHAR - Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 29th, there was short interest totalling 3,000 shares, a growth of 900.0% from the February 14th total of 300 shares. Based on an average daily volume of 2,300 shares, the short-interest ratio is presently 1.3 days.February 29, 2024 | finanznachrichten.dePharming Group N.V.: Pharming Group to report fourth quarter and full year 2023 financial results on March 14February 26, 2024 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Down to $11.75Pharming Group (NASDAQ:PHAR) Shares Gap Down to $11.75February 20, 2024 | finance.yahoo.comPharming Group N.V. (PHGN.F)February 9, 2024 | marketbeat.comPharming Group (NASDAQ:PHAR) Trading Down 4.2%Pharming Group (NASDAQ:PHAR) Trading Down 4.2%February 8, 2024 | finanznachrichten.dePharming Group N.V.: Pharming Group to participate in February investor conferencesFebruary 8, 2024 | finance.yahoo.comPharming Group to participate in February investor conferencesFebruary 5, 2024 | seekingalpha.comAstria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data ReadoutJanuary 12, 2024 | marketbeat.comShort Interest in Pharming Group (NASDAQ:PHAR) Expands By 100.0%Pharming Group (NASDAQ:PHAR - Get Free Report) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 1,000 shares, a growth of 100.0% from the December 15th total of 500 shares. Based on an average daily trading volume, of 2,500 shares, the short-interest ratio is currently 0.4 days.January 8, 2024 | markets.businessinsider.comPharming Group: Strong Buy Rating on Robust Revenue Growth and Promising Clinical Pipeline ExpansionJanuary 8, 2024 | msn.comWhat's Going On With Netherlands-Based Biopharma Company Pharming Shares Today?January 8, 2024 | seekingalpha.comPharming Group issues full-year 2023 guidanceJanuary 6, 2024 | benzinga.comPharming Stock (NASDAQ:PHAR) Dividends: History, Yield and DatesDecember 31, 2023 | marketbeat.comPharming Group (NASDAQ:PHAR) Sees Significant Decline in Short InterestPharming Group (NASDAQ:PHAR - Get Free Report) was the target of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 500 shares, a decline of 16.7% from the November 30th total of 600 shares. Based on an average trading volume of 3,200 shares, the days-to-cover ratio is currently 0.2 days.December 15, 2023 | markets.businessinsider.comBuy Rating Affirmed for Pharming Group Amid Promising Clinical Advances and FDA FeedbackDecember 13, 2023 | markets.businessinsider.comPharming To Develop Leniolisib For Additional PIDs Beyond APDS; Phase 2 Trial To Initiate In Q2December 13, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Incyte (INCY) and Pharming Group (PHAR)December 13, 2023 | finance.yahoo.comPharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)November 22, 2023 | msn.comPharming doses first paediatric patient in APDS therapy trial Get Pharming Group News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter. Email Address Tiny AI projects with huge promise hiding in plain sight … (Ad)I’ve developed a system that’s helped me find huge winners in the past. Now my system has alerted me to the next four altcoins that could be the next superstars. Click here to find out who they are. PHAR Media Mentions By Week PHAR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHAR News Sentiment▼0.700.56▲Average Medical News Sentiment PHAR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHAR Articles This Week▼171▲PHAR Articles Average Week Get Pharming Group News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ZYME News Today LYEL News Today ORIC News Today OLMA News Today GHRS News Today SLN News Today STOK News Today CVAC News Today CALT News Today PAHC News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHAR) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
